Fluconazole treatment of fungal infections in the immunocompromised host.

Immunocompromised patients are predisposed to opportunistic fungal infections. Candidiasis is reported most frequently both as a localized infection (eg, oropharyngeal candidiasis) and as life-threatening systemic candidiasis. With relatively few antifungal agents in the clinical armamentarium, the optimal management of candidiasis remains controversial. Among the agents that are available, amphotericin B is difficult to administer, 5-fluorocytosine cannot be used alone due to the frequent emergence of resistant yeasts, and ketoconazole, which is effective for esophageal and oropharyngeal candidiasis, is not recommended for systemic candidiasis, especially in granulocytopenic patients. Recently, fluconazole, a new triazole antifungal agent, has been found to be active against Candida spp and is being studied in various clinical settings. In addition to its oral formulation, it is available for intravenous (IV) administration, which is a significant advantage in treating debilitated or noncompliant patients. In a randomized, double-blind study, we compared the efficacy of 100 mg/d oral fluconazole with that of 400 mg/d ketoconazole in cancer patients with oropharyngeal candidiasis. Although clinical and microbiological outcomes were similar for both groups, relapses occurred earlier in ketoconazole- than in fluconazole-treated patients. In another study, we administered fluconazole IV 100 to 300 mg/d to 13 patients, eight of whom had fungemia. Preliminary results are encouraging. Further studies of fluconazole as prophylaxis in granulocytopenic patients and as therapy for documented systemic candidiasis are under way. These studies are expected to define specific indications for fluconazole in immunocompromised patients.

RCT Entities:   Population Interventions Outcomes